Biomarin Pharmaceutical Enterprise Value:
8.744B for May 22, 2013Biomarin Pharmaceutical Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 22, 2013 | 8.744B |
| May 21, 2013 | 8.744B |
| May 20, 2013 | 8.386B |
| May 17, 2013 | 8.606B |
| May 16, 2013 | 8.674B |
| May 15, 2013 | 9.134B |
| May 14, 2013 | 9.480B |
| May 13, 2013 | 9.279B |
| May 10, 2013 | 9.116B |
| May 9, 2013 | 8.940B |
| May 8, 2013 | 8.788B |
| May 7, 2013 | 8.801B |
| May 6, 2013 | 8.969B |
| May 3, 2013 | 8.981B |
| May 2, 2013 | 8.853B |
| May 1, 2013 | 8.560B |
| April 30, 2013 | 8.827B |
| April 29, 2013 | 8.663B |
| April 26, 2013 | 8.491B |
| April 25, 2013 | 8.448B |
| April 24, 2013 | 8.368B |
| April 23, 2013 | 8.746B |
| April 22, 2013 | 8.817B |
| April 19, 2013 | 8.805B |
| April 18, 2013 | 8.428B |
| April 17, 2013 | 8.551B |
| April 16, 2013 | 8.688B |
| April 15, 2013 | 8.486B |
| April 12, 2013 | 8.694B |
| April 11, 2013 | 8.551B |
| April 10, 2013 | 8.633B |
| April 9, 2013 | 8.388B |
| April 8, 2013 | 8.339B |
| April 5, 2013 | 8.279B |
| April 4, 2013 | 8.165B |
| April 3, 2013 | 8.213B |
| April 2, 2013 | 8.456B |
| April 1, 2013 | 8.261B |
| March 28, 2013 | 8.261B |
| March 27, 2013 | 8.006B |
| March 26, 2013 | 8.038B |
| March 25, 2013 | 8.051B |
| March 22, 2013 | 8.004B |
| March 21, 2013 | 7.937B |
| March 20, 2013 | 8.102B |
| March 19, 2013 | 8.059B |
| March 18, 2013 | 8.156B |
| March 15, 2013 | 7.621B |
| March 14, 2013 | 7.765B |
| March 13, 2013 | 7.649B |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
BMRN Enterprise Value Benchmarks
| Companies | |
|---|---|
| Cytokinetics | 109.31M |
| Array BioPharma | 671.88M |
| Alkermes | 4.418B |
BMRN Enterprise Value Rankings
| Overall |
91st percentile 703 of 8005 |
| Sector |
90th percentile 63 of 686 in Healthcare |
| Industry |
95th percentile 11 of 248 in Biotechnology |
BMRN Enterprise Value Range, Past 5 Years
| Minimum | 1.021B | Mar 9 2009 |
| Maximum | 9.480B | May 14 2013 |
| Average | 3.322B |
BMRN News
GlobeNewswire May 16
